

TENNESSEE GENERAL ASSEMBLY  
FISCAL REVIEW COMMITTEE



**FISCAL MEMORANDUM**

**SB 518 – HB 1222**

March 7, 2017

**SUMMARY OF ORIGINAL BILL:** Removes the Board of Pharmacy's (Board) oversight of certain facilities that distribute dialysate drugs or devices necessary to perform home peritoneal kidney dialysis to patients with end state renal disease if certain criteria are met. Authorizes the Board to exempt additional drugs for peritoneal dialysis from its oversight by rules.

**FISCAL IMPACT OF ORIGINAL BILL:**

NOT SIGNIFICANT

**SUMMARY OF AMENDMENT (004434):** Deletes and rewrites the bill such that the only substantive change is removing the provision that authorizes the Board to exempt additional drugs for peritoneal dialysis from its oversight by rules.

**FISCAL IMPACT OF BILL WITH PROPOSED AMENDMENT:**

**Unchanged from the original fiscal note.**

Assumptions for the bill as amended:

- The Board can update any rule change during a regularly-scheduled board meeting; therefore, any fiscal impact is estimated to be not significant.
- Based on information provided by the Department of Health, it is estimated the proposed legislation will have no impact on Board licensing fees or expenditures.
- The Board will retain oversight through licensing and regulation of all drugs for peritoneal dialysis except dialysate drugs.
- Pursuant to Tenn. Code Ann. § 4-29-121, all health related boards are required to be self-supporting over a two-year period. The Board of Pharmacy had an annual surplus of \$284,085 in FY14-15, an annual surplus of \$885,058 in FY15-16, and a cumulative reserve balance of \$2,236,772 on June 30, 2016.

**CERTIFICATION:**

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in dark ink, reading "Krista M. Lee". The signature is written in a cursive, flowing style.

Krista M. Lee, Executive Director

/jem